New Delhi: Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet.
The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19, it added. It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said. (PTI)
Follow us
Stay connected with us on our social media platforms for latest news, updates and promotions.
About Us
The Shillong Times first appeared as a tabloid weekly on 10th August 1945 under the editorship of Late Sudhindra Bhusan Chaudhuri. In 1958 it was converted to a Daily. Owing to financial constraints, within six months it reverted back to a weekly.
Latest news
Popular news
© 2025 The Shillong Times. All Rights Reserved | Crafted with IndoAge